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Conversion from cyclosporine to azathioprine at three months
reduces the incidence of chronic allograft nephropathy.
Background. Conversion from cyclosporine to azathioprine
after renal transplantation has been shown to be beneficial in
terms of allograft function, cardiovascular risk factor profile,
and the incidence of gout. A higher incidence of acute rejection,
however, has also been reported and uncertainty still exists about
the long-term outcome after conversion. We report on the ex-
tended follow-up of an open-label, randomized trial that exam-
ined conversion to azathioprine as early as three months after
transplantation.
Methods. One hundred twenty-eight patients were enrolled
in this single-center study. Three months after transplantation
they were randomly assigned to continue cyclosporine treat-
ment (N  68), or they were converted to azathioprine (N 
60). The steroid dose was temporarily increased in the patients
who were converted.
Results. Patient survival was not different in the two groups.
Graft survival tended to be lower (64.7% vs. 76.5% at 15 years)
in the cyclosporine continuation group (P  0.14) when data
were analyzed on an intention to treat basis. The graft survival
of the patients that stayed on their assigned treatment was
significantly higher in the azathioprine arm, starting at two
years’ post-transplantation. The glomerular filtration rate was
significantly higher in the patients who were converted to aza-
thioprine. More allograft biopsies were taken from patients
remaining on cyclosporine for suspicion of cyclosporine-related
nephrotoxicity and prompted a high rate of late conversions
(19%). The relative risk of chronic allograft nephropathy was
significantly higher in the group that continued cyclosporine
[relative risk, 4.3 (95% CI, 1.4 to 12.9); P 0.009]. Conversion
to azathioprine reduced the need of blood pressure and lipid-
lowering drugs.
Conclusion. Conversion to a calcineurin inhibitor–free im-
munosuppressive regiment three months after renal trans-
plantation improved allograft function, reduced the need of
cardiovascular risk factor–controlling medication, and reduced
the incidence of chronic allograft nephropathy.
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The introduction of cyclosporine A in clinical renal
transplantation has improved the efficacy of immunosup-
pressive treatment, leading to a decline in the incidence
of acute rejection episodes and allograft loss in the first
year after transplantation. However, the drug has many
toxic side effects: it raises the blood pressure and serum
cholesterol level and could cause nephrotoxicity, both
of which contribute to mortality and graft loss in the late
post-transplantation period [1]. Reducing the exposure
to the drug after the period with the highest risk of acute
rejection could, therefore, be advantageous. It was hypoth-
esized that the withdrawal of cyclosporine and the re-
placement by azathioprine, or more recently, mycophe-
nolate, after a certain post-transplantation time frame
would preserve the better short-term results of cyclospo-
rine therapy, while avoiding the consequences of long-
term exposure to the drug. As a result, a number of
clinical trials have examined the safety of cyclosporine
withdrawal after renal transplantation. Improvements
in renal function, lipid profile, hypertension, and the
incidence of gout were reported in these conversion tri-
als. Although a meta-analysis of the azathioprine conver-
sion trials reported an 11% [95% confidence interval
(CI), 7 to15] higher incidence of acute rejection after
conversion, these episodes were not associated with a
higher rate of subsequent graft loss [2].
Conversion or discontinuation of cyclosporine is still
not common practice in most transplant centers, mainly
because of uncertainty about long-term outcome. The
reported follow-up of patients in the published studies
has thus far been relatively short. Only two studies re-
ported data on patient and graft survival beyond six
years’ post-transplantation, with a maximum follow-up
of 10 years [3, 4]. In both studies, graft survival curves
tended to deviate after five years in favor of azathioprine,
but the number of patients at risk was rather limited.
Therefore, it was hypothesized that after a longer period
of follow-up a significant difference would occur.
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An open-label prospective randomized trial was ini-
tialized at our center in 1983 that compared cyclosporine
continuation with conversion to azathioprine three months
after transplantation [3]. In 1995, data on eight years’
follow-up were published; in the present report we ex-
tend the analysis of outcome to a 15-year follow-up period
and provide additional data on histologic abnormalities
seen in allograft biopsies taken during the observation
period.
METHODS
Patients and trial design
The design of this open-label randomized study has
been previously reported [3]. In summary, a total of 128
patients were enrolled in the study. Immediately after
transplantation each patient received cyclosporine and
prednisone according to a standard schedule [3]. No pro-
phylactic therapy with poly- or monoclonal T-cell anti-
bodies was given. At 3 months’ post-transplantation, pa-
tients were randomly assigned to continue cyclosporine
treatment (N  68), or were converted to azathioprine
(N 60). For patients who continued cyclosporine treat-
ment, the dose after randomization was 5 mg/kg daily
with further dose adjustments made according to whole
blood trough-level monitoring [3]. Patients who were
converted to azathioprine treatment received azathio-
prine in a dose that was gradually increased to 2 to 2.5
mg/kg daily, depending on leukocyte count. Concomitant
with the conversion, the dose of prednisone was tempo-
rarily increased and subsequently tapered slowly over a
period of 10 months to a steady dose of 10 mg/day [3].
First and third acute rejection episodes were treated with
high-dose corticosteroids. Second rejection episodes or
steroid-resistant acute rejection episodes were treated
with rabbit antithymocyte globulin. In the analysis of the
study reported in 1995, acute rejection was scored as the
institution of anti-rejection treatment [3]. A higher, but
not statistically significant, incidence of acute rejection
episodes after conversion to azathioprine was found [dif-
ference, 10.8% (95% CI, 0.2 to 22)].
For the present extended follow-up, blood pressure
values, number of antihypertensive drugs, serum choles-
terol levels, lipid-lowering therapy, and glomerular fil-
tration rate (GFR) as estimated by Nankivell’s formula
[5], were recorded 3 months, 1, 5, 10, and 15 years after
transplantation. The cyclosporine dosing was recorded
at 1 year post-transplantation.
In addition, cardiovascular events (cardiac, cerebral,
or peripheral), the occurrence (and type) of cancer, and
the cause of death were documented. We also evaluated
the number of out-of-protocol conversions to a non-
calcineurin inhibitor–based immunosuppression and the
number of patients who returned to cyclosporine ther-
apy, as well as the reasons for these changes.
Finally, the number and indication of every allograft
biopsy was assessed. The following clinical guidelines were
used to perform a percutaneous allograft biopsy: suspi-
cion of acute rejection; suspicion of recurrent/de novo
glomerulopathy as suggested by urinalysis; persistent iso-
lated proteinuria 1 g/24 hr; or a gradual loss of graft
function (20% over baseline) within the observation
period without an obvious explanation (e.g., transplant
artery stenosis or graft hydronephrosis). All pathology
reports of allograft biopsies taken during the observation
period were reviewed. Biopsy samples classified as
chronic allograft nephropathy (CAN) were re-examined
by a pathologist blinded for the instituted immunosup-
pressive regiment and scored according to the Banff 97
working classification of renal allograft pathology [6]. In
this study, CAN was defined by functional and histologic
criteria. A gradual loss of graft function (20% over
baseline) without an obvious explanation was required
in combination with biopsy findings of nonspecific pa-
thology, such as glomerulosclerosis, tubular atrophy and
interstitial fibrosis with or without peripheral nodular
arteriolar hyaline changes, arterial intimal fibrosis, or
signs of allograft glomerulopathy.
Statistical analysis
The analysis was performed on an intention-to-treat
basis. Patient survival, graft survival, and the incidence
of CAN were also analyzed separately in the patients
who were not converted from their initial study assign-
ment. Differences between therapy groups regarding
continuous numerical variables were analyzed using the
independent samples t test. Differences between ordered
categorical variables were compared by the Mann-Whit-
ney U test. Survival and occurrence rates were estimated
by the Kaplan-Meier product limit method, and factor
levels compared by the Wilcoxon-Gehan test. Cox pro-
portional hazard regression was used for estimation of
relative risks. In order to allow relative risk between
therapy groups to change over follow-up time, extended
Cox regression was used, with therapy groups defined
as time-dependent variables. Statistical analysis of the
data was performed using SPSS version 10.07 (SPSS,
Inc., Chicago, IL, USA).
RESULTS
Patient characteristics
The characteristics of the study populations are sum-
marized in Table 1. No significant differences were ob-
served [3]. The mean follow-up time of the 68 patients
who were randomized to continue cyclosporine treat-
ment was 15.2 years (range, 13.0 to 17.6), and of the
60 patients who were converted to azathioprine, mean
follow-up time was 15.4 years (range, 12.8 to 18.0).
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Table 1. Baseline characteristics of patients and determinants of
graft function and survival
Cyclosporine Azathioprine
group group
(N  68) (N  60)
Male/female 44/24 35/25
Age years 43.1 (11.9) 46.1 (10.9)
First/second transplantation 59/9 54/6
Mismatches
HLA-A: zero/one/two 33/34/1 24/34/2
HLA-B: zero/one/two 19/45/4 17/39/4
HLA-DR: zero/one/two 38/26/4 37/22/1
Highest panel reactive antibodies %a 28.1 (30.7) 30.7 (33.1)
Donor age in yearsa 34.6 (15.1) 35.9 (14.6)
Cold ischemia time hoursa 29.2 (7.6) 29 (6.4)
Warm ischemia time minutesa 24.5 (5.4) 25.2 (7.5)
Number of rejection episodes
Before randomization: 0/1/2/3 43/15/9/1 33/18/7/2
Smokers before transplantation % 29 (41%) 32 (53%)
HLA, human lymphocyte antigen.
a Mean (SD)
Adherence to treatment protocol
During follow-up, immunosuppressive therapy was
changed in 15 cyclosporine-treated patients (22%) and
in 16 patients who were converted to azathioprine (27%).
In the cyclosporine group, the main reason for out-of-
protocol switch was cyclosporine nephrotoxicity (N 
13, 87%), based on biopsy findings in 11 patients (84%);
therapy was changed because of the suspected cyclospo-
rine-related nephrotoxicity at a mean SEM of 8.6 1.4
years’ post-transplantation. Conversion to azathioprine
was performed in 7 patients, conversion to mycopheno-
late in 5, and in 1 patient a lower cyclosporine trough
level was pursued. Non-renal toxic side effects (gout and
hypertension) were a reason to convert to azathioprine
in 1 patient and to accept lower cyclosporine trough
levels in another.
The main reason to change therapy in the azathioprine
group was non-renal toxicity (N 11, 69%). Severe side
effects on liver and bone marrow were documented in
9 patients (82%). Nine patients were reconverted to
cyclosporine therapy and 2 were switched to mycopheno-
late. One patient returned to cyclosporine treatment be-
cause of chronic rejection. In 1 patient immunosuppres-
sive therapy was stopped because of post-transplant
lymphoproliferative disease. In 2 patients prednisone
was withdrawn because of steroid-related side effects
and cyclosporine was reintroduced to maintain adequate
immunosuppression. The remaining patient was recon-
verted to cyclosporine to control a nephrotic syndrome
due to recurrent glomerular disease. The reintroduction
of cyclosporine therapy in 13 patients (22% of total)
took place at a mean  SEM of 4.6  1.0 years’ post-
transplantation.
Fig. 1. Patient survival.
Patient survival, vascular events, cancer,
and causes of death
Patient survival was not significantly different in the
two groups of patients. Ten and 15 years after trans-
plantation, patient survival was 72.1% and 57.4% in the
cyclosporine group versus 73.3% and 54.8% in the aza-
thioprine group, respectively (P  0.93) (Fig. 1). The
outcome did not differ if the analysis was restricted to
patients that stayed on their initial immunosuppressive
medication. Cardiovascular mortality 15 years after
transplantation was also not significantly different among
the two study groups (cyclosporine continuation, 21.2%;
azathioprine conversion, 23.3%). Twenty patients (42.2%)
in the cyclosporine group and 17 patients (36.2%) in
the azathioprine group experienced at least one vascular
event (cardiac, peripheral, or cerebral) (P  0.57). No
difference was found in the cumulative incidence of skin
cancer after 15 years (cyclosporine group, 15.2%; azathi-
oprine group, 16%; P  0.5) or cancer of other organs
(9.7% vs. 17.7%, respectively; P  0.55).
Cardiovascular risk factors
Before transplantation, diastolic blood pressure was
4 mm Hg (95% CI, 0.3 to 7.7) higher in the azathioprine
group (Table 2); at randomization, no significant differ-
ences in systolic or diastolic blood pressure were found
between the two groups. Nine months after randomiza-
tion diastolic blood pressure was 3.5 mm Hg lower in
azathioprine group (95% CI, 03 to 6.7). No difference
in blood pressure was observed at other post-transplanta-
tion intervals. At one year, however, 20% more cyclospo-
rine-treated patients needed antihypertensive medica-
tion (95% CI, 4 to 36), and this proportion increased to
29% during follow-up (Table 2). No significant differ-
ences were found in serum cholesterol levels over time,
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Table 2. Effects on blood pressure, number of antihypertensive drugs required, serum cholesterol, and lipid-lowering therapy
0 3 months 1 year 5 years 10 years 15 years
Time post-transplantation C A C A C A C A C A C A
Systolic blood pressure N  68 N  57 N  65 N  59 N  65 N  57 N  46 N  46 N  37 N  38 N  16 N  17
Mean mm Hg 147 153 144 145 144 140 148 144 144 143 137 135
Difference (95% CI) 6 (3.5–15.5) 0.5 (6.2–7.2) 4 (2.4–10.4) 3.8 (3.8–11.4) 1.5 (8.1–11.2) 1.6 (13.2–16.3)
Diastolic blood pressure
Mean mm Hg 87 91 89 88 89 85 89 86 85 83 83 79
Difference (95% CI) 4 (0.3–7.7) 0.6 (2.7–3.9) 3.5 (0.3–6.7) 3.4 (3.8–11.4) 1.9 (2.6–6.4) 4.0 (1.5–9.4)
Number of antihyperten-
sive drugs N  67 N  55 N  64 N  58 N  65 N  57 N  47 N  46 N  37 N  38 N  16 N  17
None 47 41 17 16 12 22 6 16 2 13 0 5
One or two 18 13 42 41 45 32 35 26 25 24 11 9
Three or more 2 1 5 1 8 3 6 3 10 1 5 3
Difference (95% CI)a 5% (12–20) 1% (15–17) 20% (4–36) 22% (5–39) 29% (11–46) 29% (5–54)
Serum cholesterol N  56 N  47 N  54 N  44 N  60 N  49 N  46 N  44 N  37 N  38 N  14 N  17
Mean mg/dLb 255 259 259 263 282 278 271 263 228 236 209 220
Difference (95% CI) 0.1 (0.7–0.9) 0.1 (0.5–0.7) 0.1 (0.7–0.9) 0.2 (0.5–0.9) 0.2 (0.7–0.3) 0.3 (1.0–0.3)
Lipid-lowering therapy N  67 N  55 N  64 N  58 N  65 N  57 N  47 N  46 N  37 N  38 N  16 N  17
No 67 55 64 58 65 67 43 45 16 26 7 10
Yes — — — — — — 4 1 21 12 9 7
Difference (95% CI) 6% (3–16) 25% (3–48) 15 (21–51)
Abbreviations are: C, continued on cyclosporine; A, converted to azathioprine; CI, confidence interval.
a One or more vs. no antihypertensive drugs
b When converting to International System of Units (SI), multiply by 0.02586
Table 3. Renal function and proteinuria during follow-up
3 months 6 months 1 year 5 years 10 years 15 years
Time post-transplantation C A C A C A C A C A C A
Estimated GFR N  68 N  60 N  67 N  60 N  66 N  57 N  50 N  46 N  37 N  38 N  15 N  17
Mean mL/min 56.5 53.5 57.3 67.8 55.7 72.9 56.3 71.0 52.8 71.7 56.3 71.7
Difference (95% CI) 3.0 (2.6–8.6) 10.4 (5.0–15.9) 17.1 (11.6–22.7) 14.8 (7.7–21.9) 19.0 (10.1–27.8) 15.7 (0–30.6)
Proteinuria N  68 N  59 N  67 N  57 N  66 N  57 N  49 N  46 N  37 N  38 N  16 N  17
1 g/day 62 56 60 51 59 49 42 38 33 30 14 15
1 6 3 7 6 7 8 7 8 4 8 1 2
Difference (95% CI)‡ 4% (5.3–13) 0.1% (11–11) 3% (15–8) 3% (18–12) 10% (27–7) 5% (27–17)
Abbreviations are: C, continued on cyclosporine; A, converted to azathioprine; GFR, glomerular filtration rate; CI, confidence interval.
‡1 g/day vs. 1/day
but more patients in the cyclosporine group needed lipid-
lowering therapy, which was only significant at 10 years
(Table 2).
Graft survival
Graft survival censored for death with a functioning
graft at 10 and 15 years was 75.3% and 64.7%, respec-
tively, in the cyclosporine group versus 85.4% and
76.5%, respectively, in the azathioprine group (P 0.14)
(Fig. 2). Although the study was not designed to detect
differences in late graft loss, the graft survival curves
tended to deviate with time. Therefore, we divided the
follow-up time into different periods: 2 years’, 2 to 5
years’, and 5 years’ post-transplantation. The relative
risk (RR) of graft loss in the cyclosporine group com-
pared to the azathioprine group increased with time—RR
in the first 2 years of follow-up, 0.88 (95% CI, 0.22 to
3.50), P  0.85; RR between 2 and 5 years follow-up,
1.54 (95% CI, 0.37 to 6.46), P  0.55; and RR beyond
5 years of follow-up, 2.90 (95% CI, 0.92 to 9.07), P 
0.070. When we analyzed the outcomes restricted to
those who were not converted from their initial assign-
ment we found a significantly better graft survival in the
azathioprine group starting at two years’ post-trans-
plantation; graft survival censored for death with a func-
tioning graft at 2, 5, 10, and 15 years was 94.7 vs. 93.7%,
92.7 vs. 85.2%, 90.0 vs. 74.1%, and 81.9 vs. 69.2%, respec-
tively (P  0.012) (Fig. 3). The RR of graft loss after
two years’ post-transplantation in the cyclosporine group
compared to the azathioprine group was 3.23 (95% CI,
1.05 to 9.94; P  0.013); the RR of graft loss in the first
two years did not differ between the groups and was
1.16 (95% CI, 0.26 to 5.18; P  0.90).
In both treatment arms the major cause of graft loss
was death with a functioning graft: 22 patients (32%) in
the cyclosporine group versus 23 (38%) in the azathio-
prine group. A gradual loss of function resulting in graft
failure was seen in 18 patients (26%) who continued
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Fig. 2. Graft survival censored for death with a functioning graft.
cyclosporine. In 16 of these patients a biopsy was per-
formed that showed CAN in 12 (75%), and recurrent
renal disease in 4 patients (25%). In contrast, only 8
patients (13%) in the azathioprine group developed graft
failure due to a gradual decline in function. Six patients
were biopsied, showing CAN in 4 patients (67%) and
recurrent renal disease in 2 patients (33%). Acute rejec-
tion resulted in graft loss in 2 patients who continued
cyclosporine (3%) versus 3 patients (5%) who switched
to azathioprine treatment. In one patient in the azathio-
prine group, graft artery thrombosis, and in another pa-
tient, the cessation of immunosuppressive treatment be-
cause of post-transplant lymphoproliferative disease,
resulted in loss of the graft.
Graft function and proteinuria
Glomerular filtration rate, as estimated by Nankivell’s
formula, was significantly better in the patients who were
converted to azathioprine (Table 3). Three months after
conversion the difference measured 10.4 mL/min (95%
CI, 5 to 15.9 mL/min), increased to 17.1 mL/min (95% CI,
11.6 to 22.7) at 9 months after conversion, and persisted
throughout the follow-up. No significant difference be-
tween the groups in the proportions of patients with
proteinuria over 1 g/24 hr was found at any point in time.
Cyclosporine dosing
The mean dose of cyclosporine taken at one year post-
transplantation in the cyclosporine arm of the study mea-
sured 5.1  1.4 mg/kg. The cyclosporine dosage did not
differ between the patients who developed CAN or lost
their graft function compared to those who did not (CsA
mg/kg groups: CAN yes/no, graft loss yes/no, CAN, or
graft loss yes/no, mean  SD, 5.6  1.4 vs. 5.0  1.3;
4.8  1.7 vs. 5.2  1.2; 5.3  1.6 vs. 5.0  1.2 mg/kg; P 
Fig. 3. Graft survival censored for death with a functioning graft of the
patients that stayed on the drug to which they were initially assigned.
Vertical dashed lines indicate the start of the study 3 months’ post-
transplantation (left lines), and the start of the period of survival benefit
in the azathioprine arm of the study 2 years’ post-transplantation (right
lines).
0.15, P 0.28, P 0.61). The mean cyclosporine trough
levels at one year post-transplantation were not signifi-
cantly different between the patients of the cyclosporine
group who developed CAN and those who did not. The
results were similar when the analysis was limited to
those who stayed on cyclosporine treatment.
Analysis of allograft biopsies
In order to evaluate the adherence to the biopsy guide-
lines we reassessed the indications for the biopsies that
were taken in the follow-up period (Table 4). No signifi-
cant differences were found between the two groups with
respect to the performance of a biopsy for a specific
indication. We analyzed the histopathologic findings in
biopsies that were obtained more than 6 months after
randomization. A total number of 53 biopsies were iden-
tified, 33 in the cyclosporine group, and 20 in the azathio-
prine group. Forty-seven biopsies (89%) yielded ade-
quate material according to the Banff criteria. Of these,
30 biopsies (64%) were taken in the group that continued
cyclosporine and 17 (36%) in the group that switched
to azathioprine (Table 5). Acute rejection was found in
2 patients of the cyclosporine group (3%) and in 3 pa-
tients of the azathioprine group (5%). Recurrent or de
novo glomerulopathy was found in 8 patients in the
cyclosporine group (11.8%) and in 7 patients of the aza-
thioprine group (11.7%). CAN was diagnosed in 16 pa-
tients of the cyclosporine group (23.5%), but in only 4
patients of the azathioprine group (6.4%). In the cyclo-
sporine group 15 patients received the drug until the
diagnosis of CAN. None of the patients in the azathio-
prine group received cyclosporine prior to the diagnosis.
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Table 4. Clinical indications and number of biopsies
Cyclosporine group Azathioprine group
Indication No. % No. biopsies performed % No. % No. biopsies performed % P valuea
Suspicion of acute rejection 12 (25%) 11 (92%) 11 (32%) 11 (100%) 1.000
Persistent proteinuria 4 (8%) 4 (100%) 7 (21%) 6 (85%) 1.000
Recurrent or de novo glomerulopathy 5 (10%) 5 (100%) 3 (9%) 3 (100%) 1.000
Chronic transplant dysfunction 27 (56%) 24 (88%) 13 (38%) 10 (77%) 0.370
Total 48 (100%) 44 (92%) 34 (100%) 30 (88%) 0.713
a For the difference in biopsy performance between the cyclosporine and the azathioprine group
Table 5. Biopsy results in samples taken more than six months post-randomization
Cyclosporine group Azathioprine group
Biopsy diagnosis No. biopsies % No. patients % No. biopsies % No. patients %
Acute rejection 3 (10%) 2 (3%) 3 (18%) 3 (5%)
Glomerulopathy (recurrent/de novo) 11 (37%) 8 (11.8%) 9 (53%) 7 (11.7%)
Chronic allograft nephropathy 16 (53%) 16 (23.5%) 5 (29%) 4 (6.4%)
Total 30 26 17 14
The relative risks of biopsy-proven late acute rejection
or recurrent/de novo glomerulopathy did not differ be-
tween the two groups. The relative risk of biopsy-proven
CAN during the follow-up period was significantly
higher in the group that continued cyclosporine [RR 4.3
(95% CI, 1.4 to 12.9); P  0.009] (Fig. 4). Similar results
were obtained when the analysis was restricted to pa-
tients who stayed on their initial immunosuppressive
medication.
The Banff score of the biopsy samples that were diag-
nosed as CAN are depicted in Table 6. Eight biopsy
samples in the cyclosporine group (50%) showed signs
suggestive of chronic rejection (transplant glomerulopa-
thy and/or pronounced arterial intimal fibrosis); in 5 of
these peripheral nodular arteriolar hyaline changes were
also found, reminiscent of cyclosporine nephrotoxicity.
In another 8 biopsy specimens of the cyclosporine group,
peripheral nodular arteriolar hyaline changes were seen
without signs suggestive of chronic rejection. A higher
score was found for peripheral nodular arteriolar hyaline
change in the cyclosporine group and a higher score for
the degree of intimal fibrosis in the azathioprine group
(Table 6). These histologic data suggested that continued
cyclosporine treatment 3 months’ post-transplantation
did not give better protection against chronic rejection
than when a switch to azathioprine was performed. The
higher incidence of CAN during continued cyclosporine
treatment is most likely explained by additional cyclo-
sporine-related renal structural changes.
DISCUSSION
The present paper is the first to report the results of
more than 10 years’ follow-up of a single-center, open,
Fig. 4. Cumulative incidence of chronic allograft nephropathy (CAN).
randomized trial comparing cyclosporine withdrawal and
conversion to azathioprine with continued cyclosporine
treatment. The conversion to azathioprine took place as
early as 3 months’ post-transplantation. The results show
that the earlier reported beneficial effects of conversion
on cardiovascular risk factor control extend beyond 5
years’ post-transplantation. Furthermore, allograft func-
tion is better preserved after conversion and a lower
incidence of CAN is found.
In the intention-to-treat analysis of our study a better
graft survival was observed in the azathioprine group
beyond 5 years of follow-up, albeit not significant, and
the relative risk of graft loss in the cyclosporine-treated
patients increased with time. It has been shown that a
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Table 6. Pathologic findings of biopsies diagnosed as chronic allograft nephropathy
Cyclosporine group Azathioprine group
Histologic features (N  16) (N  4) P value
Interstitial fibrosisa 1.500.16b 1.50.29 0.914
Tubular atrophya 1.370.27 1.50.29 0.768
Arterial intimal thickeninga 1.250.27 2.50.29 0.039
Allograft glomerulopathya 0.190.10 0 0.360
Peripheral arteriolar hyaline changea 1.250.93 0 0.017
Percentage global glomerulosclerosis 387.2 1911.1 0.283
a Scored according to the Banff 97 classification on a scale of 0 to 3 [6]
b Mean  SEM
reduction in dose or withdrawal of calcineurin inhibitors
slows the rate of decline in renal function of patients
with CAN [7]. The observed graft survival benefit after
conversion to azathioprine in our study may have been
significantly weakened by the high rate of late cyclospo-
rine withdrawals in the cyclosporine continuation group
due to cyclosporine-related nephrotoxicity (19%). When
we analyzed the outcomes restricted to those who were
not converted from their initial assignment, we found a
significantly better graft survival in the azathioprine
group starting at two years’ post-transplantation and the
cumulative incidence of CAN was still significantly lower
in the patients who used azathioprine. The lag time seen
in the present study before the nephrotoxic effect of
cyclosporine started to influence the graft survival curve
confirms previous observations after conversion to aza-
thioprine [4], and compares well with data on cyclospo-
rine-induced irreversible nephrotoxicity observed in car-
diac allograft recipients [8].
The estimated GFR values improved after conversion
to azathioprine: 3 months after conversion the mean
GFR was 10.4 mL/min higher. This increase can be ex-
plained by the disappearance of cyclosporine-induced
renal vasoconstriction [9]. However, since the difference
in GFR tended to increase further at a longer period of
follow-up, these data also suggest reversibility of renal
structural changes after cyclosporine withdrawal.
The pathologic changes that are found in chronic dete-
riorating kidney allografts are often not specific [10]. The
descriptive term chronic allograft nephropathy (CAN)
that has been adopted to classify these changes encom-
passes chronic obliterative vascular alterations, tubular
atrophy, glomerulosclerosis, and interstitial fibrosis [6].
CAN includes both changes due to chronic rejection and
chronic calcineurin inhibitor nephrotoxicity. Herein, we
report for the first time a beneficial effect of cyclosporine
withdrawal on the incidence of CAN post-transplanta-
tion. The fact that the pathology data in our study were
derived from kidney biopsies performed for cause
prompted us to reassess the indication and the actual
performance of a biopsy. We found no difference in
biopsy performance for a specific indication in the two
study arms.
In our study cyclosporine trough levels were moni-
tored routinely in the patients who continued cyclospo-
rine, and dosing was adjusted accordingly. In spite of
this, cyclosporine use had a marked influence on the
incidence of CAN. The mean dose of cyclosporine taken
at one year post-transplantation in the patients who con-
tinued on cyclosporine was 5.1  1.4 mg/kg, which com-
pares well with the optimal dose defined by data obtained
from the Collaborative Transplant Study registry. A
cyclosporine dose of 3 to 6 mg/kg at one year was associ-
ated with better long-term allograft survival [11]. In our
study, no difference was found in cyclosporine dosage
at 1 year post-transplantation between the patients of
the cyclosporine group who did or did not develop CAN
or who lost their transplant. Also, the mean cyclosporine
trough levels at one year were not significantly different.
Recently, new and better ways to monitor cyclosporine
exposure of individual patients have been investigated
to optimize its efficacy and to decrease toxic side effects.
It has been shown that cyclosporine exposure measured
by the area under the concentration over time curve
(AUC) is highly variable among patients who have equal
cyclosporine trough levels [12]. Formally, we cannot ex-
clude that a proportion of our patients in the cyclospo-
rine continuation group was overexposed to the drug
and that better monitoring of cyclosporine therapy will
reduce the incidence of cyclosporine nephrotoxicity and
the occurrence of CAN post-transplantation.
The finding that conversion to non-calcineurin immu-
nosuppressive treatment reduces the long-term inci-
dence of CAN is of special importance in an era of donor
shortage, with an increasing use of kidneys from marginal
donors [13–15]. The recipients of these kidneys are likely
to be more prone to graft failure as a result of cyclospo-
rine nephrotoxicity than the recipients of a regular allo-
graft merely because they cannot tolerate some loss of
function [16].
The single most important cause of graft loss in both
treatment arms of our study was death with a functioning
graft, which was usually related to a cardiovascular event
[17–21]. Renal transplant patients, after the first post-
transplant year, experience a five-fold increase in cardio-
vascular mortality compared with age-matched controls
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[19]. This stresses the need to reduce cardiovascular risk
factors both before and after transplantation. The with-
drawal of cyclosporine and replacement by azathioprine
3 months after transplantation reduced the need of car-
diovascular risk–controlling medication over the entire
15-year period of follow-up.
The question can be raised whether every patient
should be converted to a non-calcineurin–based immu-
nosuppressive regimen after a certain period of time. It
is important to note that our study was performed in
a cohort of predominantly Caucasian recipients, well
matched for human lymphocyte antigen (HLA), and
therefore the results cannot directly be extrapolated to
other populations [16, 22–24]. Furthermore, the conver-
sion to azathioprine was not completely harmless, as
substantial toxicity of azathioprine therapy was encoun-
tered. In fact, the results of this study should encourage
the use of mycophenolate as the “conversion agent” of
choice rather than azathioprine. Mycophenolate therapy
has a better safety profile than azathioprine, has been
associated with less acute rejection after conversion com-
pared to azathioprine, and may by itself, according to
U.S. renal transplant scientific registry data, further de-
crease the incidence of CAN [25–29].
CONCLUSION
Cyclosporine withdrawal three months after trans-
plantation can be done safely, reduces the need of cardio-
vascular risk factor–controlling medication, improves al-
lograft function, and reduces the incidence of CAN.
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